NEWSROOM

KALY

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

May 5, 2021

  Sandusky, OH, May 5, 2021 – -- PAO Group, Inc. (USOTC: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING...

read more

PAOG CBD Nutraceuticals To Hit Market This Year

May 4, 2021

  Sandusky, OH, May 4, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT...

read more

PAOG 2021 CBD Nutraceutical Sales Rollout Plan Presentation Scheduled This Friday

May 3, 2021

  Sandusky, OH, May 3, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to present the company’s CBD Nutraceutical Sales Rollout Plan this Friday, May 7, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT...

read more

PAOG Anticipates Boost To CBD Pharmaceutical Research Initiative From Improving Cannabis Legalization Outlook

Apr 28, 2021

  Sandusky, OH, April 28, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today highlighted recent cannabis legalization progress anticipated to enhance PAOG’s ongoing CBD Pharmaceutical Development Program. PAOG has partnered with Puration, Inc. (OTC Pink: PURA) to build a pharmaceutical grade indoor hemp grow facility and CBD extraction facility in conjunction with PURA’s Farmersville Hemp Brand project in Texas.  PURA Farmersville Hemp Brand project partners also include Alkame Holdings,...

read more

PAOG Announces Opportunity To Expand CBD Pharmaceutical Research

Apr 13, 2021

  Sandusky, OH, April 13, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today released a management update on the company’s ongoing CBD Pharmaceutical Development Program. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS...

read more

PAOG CBD Pharmaceutical Development Update Coming Tomorrow, Tuesday April 13, 2021

Apr 12, 2021

  Sandusky, OH, April 12, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960...

read more

PAOG Advances CBD Pharmaceutical Developments Backed By US Patent

Apr 8, 2021

  Sandusky, OH, April 8, 2021 – --  PAO Group, Inc. (OTC Pink: PAOG) today announced a management update on the company’s ongoing CBD Pharmaceutical Development Program progress scheduled to be released next week on Tuesday, April 13, 2021. Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960...

read more

PAOG Targets September 2021 To Introduce CBD Nutraceuticals To Market Co-Packed By ALKM and Marketed Through USMJ

Mar 16, 2021

  Sandusky, OH, March 16, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today released details on the company’s nutraceutical developments initiative following last week’s introduction of adding CBD RELAX-RX to existing CBD RespRx developments.  The details today are highlighted by the company’s September 2021 go-to-market target date with nutraceutical co-packing to be conducted by Alkame Holdings, Inc. (OTC Pink: ALKM) and product marketing to be conducted by North American Cannabis...

read more

PAOG Announces RELAX-RX Nutraceutical For $18 Billion Anxiety And Depression Treatment Market

Mar 8, 2021

  Sandusky, OH, March 8, 2021 – -- PAO Group, Inc. (OTC Pink: PAOG) today announced initiating the development of its new nutraceutical, RELAX-RX, targeting the anxiety and depression treatment market anticipated to reach a value of $18 billion by 2025. The company recently announced plans to produce a variety of nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). Last...

read more

PAOG Plans To Add CBD Nutraceutical Revenue In 2021 To Cannabis Cultivation Revenue

Feb 10, 2021

  Sandusky, OH, February 10, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to add revenue this year in 2021 from its developing CBD nutraceutical business to currently anticipated revenue from its cannabis cultivation business revenue. PAOG recently announced that it anticipated reporting approximately $50,000 in revenue in Q4 2020 from its cannabis cultivation business acquired last year from Puration, Inc. (OTC PINK: PURA).  The Q4 2020 revenue anticipated...

read more

PAOG Announces CBD Nutraceuticals Expansion Plan For $3.8 Billion Market Presentation Scheduled Next Week

Feb 8, 2021

  Sandusky, OH, February 8, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced plans to publish a multimedia presentation next week on the company’s strategy to expand its nutraceutical product reach.  The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). The presentation is scheduled to be published next week on Tuesday, Feb 16th. Last...

read more

PAOG To Expand Revenue Base Introducing New CBD Nutraceuticals Targeting $3.8 Billion Market

Feb 4, 2021

  Sandusky, Ohio, February 4, 2021 - - PAO Group, Inc. (OTC Pink: PAOG) today revealed plans to expand its nutraceutical product reach. The company plans to produce nutraceuticals for additional applications beyond the current focus on care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD). Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary...

read more

PAOG Confirms $300,000 Sales Agreement With Cannabis Cultivation Subsidiary

Feb 3, 2021

  Sandusky, OH, February 3, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed a $300,000 sales agreement executed by the company’s cannabis cultivation subsidiary. PAOG anticipates approximately $50,000 in revenue per quarter for six quarters starting with an estimated $50,000 in revenue expected to be reported for Q4 2020. Last summer, PAOG acquired a cannabis cultivation business from Puration, Inc. (OTC PINK: PURA). The acquisition was made in conjunction with PAOG’s overall...

read more

PAOG Confirms CBD Nutraceutical Development And Distribution Partners

Feb 2, 2021

  Sandusky, OH, February 2, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed its plans to develop and distribute cannabis nutraceuticals with Alkame Holdings, Inc. (OTC PINK: ALKM) and North American Cannabis Holdings, Inc. (OTC PINK: USMJ) as partners. PAOG recently engaged with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing...

read more

PURA In Partnership With PAOG and ALKM Prepare For Biden Bull Cannabis Market

Jan 20, 2021

Dallas, TX, January 20, 2021 – -- Puration, Inc. (OTC PINK: PURA) in conjunction with its recent Farmersville partnership with PAO Group, Inc. (OTC PINK: PAOG) and Alkame Holdings Inc. (OTC PINK: ALKM) today highlighted management’s outlook for a 2021 breakout on the Farmersville strategy in light of an anticipated President Biden cannabis bull market. In an article today from The Motley Fool: “It's true that Biden hasn't been a big fan of marijuana legalization. But the prospects of federal...

read more

PAOG Publishes 2021 Cannabis Biopharmaceutical Strategic Outlook

Jan 14, 2021

  Sandusky, OH, January 14, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today published a management outlook for 2021 on the company’s strategy to develop and monetize the cannabis assets acquired last year.  The strategic outlook is included in its entirety below: PAOG 2021 Cannabis Biopharmaceutical Strategic Outlook PAOG is a longtime participant in the cannabis sector working on initiatives to introduce cannabis treatments as alternatives to traditional pharmaceuticals, particularly...

read more

PAOG Dividend Update Included In 2021 Cannabis Biopharmaceutical Strategic Update Tomorrow

Jan 13, 2021

  Sandusky, OH, January 13, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced the upcoming update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook scheduled for tomorrow, Thursday Jan 14th, 2021, will include an update on the planned PAOG stock dividend to shareholders of Puration, Inc. (OTC PINK: PURA) in conjunction with PAOG’s acquisition of hemp cultivation business from PURA. In 2020, PAOG acquired a hemp cultivation business from...

read more

PAOG Confirms Cannabis Biopharmaceutical Strategic Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Jan 12, 2021

Sandusky, OH, January 12, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY). RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented...

read more

PAOG Cannabis Pharmaceutical and Nutraceutical 2021 Strategy Update Targeting $50 Billion Market Scheduled Thursday Jan 14, 2021

Jan 11, 2021

  Sandusky, OH – January 11, 2021 – PAO Group, Inc. (OTC PINK: PAOG) today announced an update covering the company’s 2021 cannabis pharmaceutical and nutraceutical development outlook is scheduled this Thursday Jan 14th, 2021. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY).  RespRx is a cannabis treatment under development for Chronic Obstructive Pulmonary Disease (COPD) derived from a patented...

read more

PAOG Confirms Q4 2020 Revenue From Cannabis Asset Acquisition

Jan 8, 2021

  Sandusky, OH, January 8, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today confirmed that the company expects to realize and report in Q4 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled...

read more

PAOG Takes Major CBD Pharmaceutical Development Step Forward

Jan 5, 2021

  Sandusky, OH, January 5, 2021 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced a major step forward in the development of a CBD pharmaceutical product. PAOG today announced an engagement with Veristat, Inc., a contract research organization headquartered in Southborough Massachusetts.  PAOG has engaged Veristat to assist in advancing PAOG with its proprietary Cannabidiol (CBD) extract for the treatment of Chronic Obstructive Pulmonary Disorder (COPD) toward initiating an...

read more

PAOG Expects To Report First Post Acquisition Revenue In Q4 2020

Dec 22, 2020

Sandusky, OH, December 22, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced that the company expects to realize and report in Q3 2020 the first revenue from assets acquired in the course of 2020. In 2020, PAOG acquired a hemp cultivation business from Puration, Inc. (OTC PINK: PURA) and RespRx from Kali-Extracts, Inc. (OTC PINK: KALY) RespRx is a cannabis treatment under development for COPD derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled...

read more

PAOG Develops CBD Nutraceutical For $12.7 Billion Market From Patented Extract Process

Dec 18, 2020

  Sandusky, OH, December 18, 2020 - - PAO Group, Inc. (OTC US: PAOG) today announced the company expects to generate its first revenue next year in 2021 from its Cannabidiol (CBD) extraction technology, RespRx, acquired in July of this year, 2020. Yesterday, PAOG announced an engagement with the Puerto Rico Consortium for Clinical Investigation (PRCCI) to assist PAOG with developing its proprietary CBD extract into a nutraceutical product to provide care for those experiencing issues...

read more

PAOG Announces Puerto Rico Consortium For Clinical Investigation Engagement To Advance CBD COPD Nutraceutical Care Solution

Dec 17, 2020

  Sandusky, OH, December 17, 2020 – -- PAO Group, Inc. (OTC US: PAOG) today announced an engagement with the Puerto Rico Consortium for Clinical Investigation to assist PAOG with developing its proprietary Cannabidiol (CBD) extract into a nutraceutical product to provide care for those experiencing issues associated with Chronic Obstructive Pulmonary Disorder (COPD).     On July 30, 2020, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC US: KALY) RespRx is a cannabis treatment...

read more

PAOG Signs Clinical Research Organization (CRO) To Advance Respiratory Cannabis Treatment Through Regulatory Approval

Oct 23, 2020

Sandusky, OH – October 23, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced executing a master services agreement with a clinical research organization in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG signed the agreement yesterday, prior to the comprehensive corporate update scheduled for publication today and included in its entirety below. Corporate Update Less than ninety days ago, PAOG...

read more

PAOG Advances FDA Application Process For Respiratory Cannabis Drug Treatment

Oct 20, 2020

Sandusky, OH – October 20, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced the company plans to release a new key update this Friday, October 23, 2020, on its progress to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG announced last week that it anticipates soon entering into an agreement with a contract research organization (CRO) making a major breakthrough in advancing PAOG’s RespRx treatment for Chronic Obstructive...

read more

PAOG and PURA Announce Free Hemp Seed Giveaway To Promote CBD and Hemp Awareness

Oct 16, 2020

Sandusky, OH – October 16, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) and Puration, Inc. (OTC PINK: PURA) today announced a free hemp seed giveaway in conjunction with the recent partnership between the two companies where PAOG will be building a hemp cultivation facility on PURA’s Farmersville, Texas property.     PAOG’s hemp cultivation facility is central to the company’s plans to develop a proprietary pharmaceutical grade hemp cultivar.     PURA recently announced a...

read more

PAOG Releases Cannabis Drug Development Update

Oct 15, 2020

Sandusky, OH – October 15, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today published a progress update on the company’s ongoing initiative to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA).  PAOG anticipates entering into an agreement with a contract research organization (CRO) within the next two weeks.  The CRO engagement will be a major breakthrough in advancing PAOG’s RespRx treatment for Chronic Obstructive Pulmonary Disease (COPD)...

read more

PAOG CEO Jim DiPrima Answers Questions About Cannabis Investigational New Drug Application Plans With FDA

Oct 2, 2020

Sandusky, OH – October 2, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced an interview of CEO Jim DiPrima on MoneyTV where Mr. DiPrima discusses recent news regarding PAOG’s latest moves to engage a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA). MoneyTV is the internationally syndicated television program all about money and what makes it happen, (http://www.moneytv.net), featuring...

read more

PAOG Engages Saul Kaye, Founder of iCAN: Israel-Cannabis and CannaTech To Prepare RespRx For IND

Oct 1, 2020

Sandusky, OH – October 1, 2020 – -- PAO Group, Inc. (OTC PINK: PAOG) today announced engaging Saul Kaye the founder of iCAN (www.israel-cannabis.com) and CannaTech (www.canna-tech.co) to provide an independent review of PAOG’s RespRx research for the treatment of Chronic Obstructive Pulmonary Disease (COPD), and to help prepare RexpRx for engaging with a contract research organization (CRO) to advance an investigational New Drug application (IND) with the Food and Drug Administration (FDA)....

read more

Categories

Mcap MediaWire - Costumer Service

Translate »